2021-02-05 · Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for AUPH shares is $11.50 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on AUPH stock is a recommendation set at 1.70.

Aurinia Pharmaceuticals (Aurinia Pharmaceuticals: AUPH) stock research, analysis, profile, news, analyst ratings, key statistics, fundamentals, stock price, charts, earnings, guidance and peers. You can purchase shares of Aurinia Pharmaceut

Aurinia Pharmaceuticals Inc. 12.79. Delayed Data. As of 4:00pm ET. -0.185 / -1.43%. Today’s Change. 12.01.

Auph price target

Good for AUPH and shareholders - and of course for patients! Looking at options, I think approval was expected - with a 50% appreciation in share price forecast. My guess is a jump to about $21-22. 2008-06-27 2021-01-25 Rigel Pharmaceuticals price target raised to $11 from $8 at H.C. Wainwright 02/18/21 Piper Sandler Rigel share setup 'distinctly positive' after Lilly deal, says Piper Sandler 02/12/21 Cowen Eli Lilly price target raised to $235 from $195 at Cowen 02/08/21 SVB Leerink AbCellera price target … The analyst raised his price target from $9.00 to $11.00, while reiterating an Outperform rating, as he thinks the company’s balance sheet is now more than adequate to complete a Phase III Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH / TSX: AUP) (Aurinia or the Company) today announced a favorable assessment regarding the cost-effectiveness and value of LUPKYNIS™ (voclosporin), based on an independent analysis issued by the Institute for Clinical and Economic Review (ICER) in a revised Evidence Report issued on March 12, 2021. 8 Wall Street analysts have issued ratings and price targets for Aurinia Pharmaceuticals in Their average twelve-month price target is $28.50, suggesting a possible upside of 122.1%. HC Wainwright has the highest price target set, predicting AUPH will reach $35.00 in the next twelve months. BTIG Research has the lowest price target set, forecasting a price of $20.00 for Aurinia Pharmaceuticals in the next year.

8 Wall Street analysts have issued ratings and price targets for Aurinia Pharmaceuticals in

As for revenue growth, note that AUPH's revenue has grown 15,660.38% over the past 12 months; that beats the revenue growth of 99.86% of US companies in our set. Analyst Ratings For Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) Today, Royal Bank of Canada raised its price target on Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) to $11.00 per share. There are 3 Buy 2021-02-26 2019-01-01 Is AUPH a Buy (Price Target) by Finance BroGet a FREE Stock Valued up to $500 with Robinhood - https://join.robinhood.com/zacharf1031Love our content?

View Price Target for AUPH Access over 100 stock metrics like Beta, EV/EBITDA, PE10, Free Cash Flow Yield, KZ Index and Cash Conversion Cycle. Start your free 7-Day Trial. Start My Free Trial No credit card required. Already a subscriber? Sign in.

There are currently 1 hold rating and 7 buy ratings for the stock, resulting in a consensus rating of "Buy." Use the points listed below to better contextualize what this analyst price target and recommendations data data means for investors. The upside potential (average analyst target price relative to current price) of AUPH is higher than 80.67% of all US stocks. The variance in analysts' estimates of AUPH is less than 22.12% of all US stocks. This price target is based on 8 analysts offering 12 month price targets for Aurinia Pharmaceuticals in the last 3 months. The average price target is $28.50, with a high forecast of $35.00 and a low forecast of $20.00. The average price target represents a 122.14% upside from the last price of $12.83. Based on analysts offering 12 month price targets for AUPH in the last 3 months.

Their average twelve-month price target is $28.50, predicting that the stock has a possible upside of 120.93%. The high price target for AUPH is $35.00 and the low price target for AUPH is $20.00. There are currently 1 hold rating and 7 buy ratings for the stock, resulting in a consensus rating of "Buy." Use the points listed below to better contextualize what this analyst price target and recommendations data data means for investors. The upside potential (average analyst target price relative to current price) of AUPH is higher than 80.67% of all US stocks. The variance in analysts' estimates of AUPH is less than 22.12% of all US stocks. This price target is based on 8 analysts offering 12 month price targets for Aurinia Pharmaceuticals in the last 3 months.
Venstre parti norge

Volume 1,158,335.

Earnings are forecast to grow 62.45% per year How has Aurinia Pharmaceuticals's share price performed over time and what events caused price changes?

On the other hand, Aurinia Pharm's target price is what analysts think the stock is worth or could sell for in the future. Based on our forecasts, a long-term increase is expected, the "AUPH" stock price prognosis for 2026-04-03 is 35.896 USD. With a 5-year investment, the revenue is expected to be around +180%. View Price Target Upside (Daily) for AUPH Access over 100 stock metrics like Beta, EV/EBITDA, PE10, Free Cash Flow Yield, KZ Index and Cash Conversion Cycle.

Nuvida biotech

View the latest AUPH stock quote and chart on MSN Money. Dive deeper with interactive charts and top stories of Aurinia Pharmaceuticals Inc..

View the latest AUPH stock quote and chart on MSN Money. Dive deeper with interactive charts and top stories of Aurinia Pharmaceuticals Inc.. Good for AUPH and shareholders - and of course for patients! Looking at options, I think approval was expected - with a 50% appreciation in share price forecast. My guess is a jump to about $21-22. It looks like 12.81 has been a support level on four different occasions for AUPH. It also looks like the sell off is overblown with an RSI of 36.

Based on analysts offering 12 month price targets for AUPH in the last 3 months. The average price target is $ 0.00 with a high estimate of $ 0.00 and a low estimate of $ 0.00 .

Volume today is more active than usual. So far 1,856,253 shares have traded compared to average volume of 1,294,410 shares. It looks like 12.81 has been a support level on four different occasions for AUPH. It also looks like the sell off is overblown with an RSI of 36. Im looking for a bounce up the fibonacci scale . $14.12 is my target over the next few trading days.

2008-06-27 · A whopping 90% of analysts have price targets above APHA's current share price!!! Holy cow! Every line of resistance imaginable points to an rocket in either direction, though they point more upward than downward. There's been a wedge for the past year, and an FDA approval Friday could turn this into either a WeWork or a Tesla. We will see. View the latest AUPH stock quote and chart on MSN Money. Dive deeper with interactive charts and top stories of Aurinia Pharmaceuticals Inc..